Implementing precision medicine initiatives in the clinic: A new paradigm in drug development

Current Opinion in Oncology

Volumn 26, Issue 3, 2014, Pages 340-346

  Hollebecque, Antoine ^a   Massard, Christophe ^a   Soria, Jean Charles ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

cancer; drug development; genomics; personalized medicine; phase I

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; DRUG SCREENING; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HOSPITAL CARE; HUMAN; MEDICAL TECHNOLOGY; MEDICATION THERAPY MANAGEMENT; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRECISION MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899475026     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000077     Document Type: Review

References (66)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-724.
2. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012; 30:647-660.
3. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature 2013; 501:355-364.
4. Dienstmann R, Rodon J, Tabernero J, et al. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol 2013; 25:305-312.
5. De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 2013; 18:1180-1188.
6. Sleijfer S, Bogaerts J, Siu LL, et al. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013; 31:1834-1841.
7. Verweij J, de Jonge M, Eskens F, et al. Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. Mol Oncol 2012; 6:196-203.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
9. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-2394.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
11. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.
12. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-1392.
13. Hollebecque A, Postel-Vinay S, Verweij J, et al. Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Eur J Cancer 2013; 49:1515-1520.
14. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4:e7887.
15. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-4883.
16. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of nonsmall-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616-2624.
17. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383.
18. Dienstmann R, Serpico D, Rodon J, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012; 11:2062-2071.
19. Andre F, Bachelot TD, Campone M, et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): a prospective multicentric trial (SAFIR01). ASCO Meeting Abstracts 2013; 31 (15-suppl):511.
20. Bedard PL, Oza AM, Tsao M-S, et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). ASCO Meeting Abstracts 2013; 31 (15-suppl):11002.
21. Hollebecque A, Massard C, De Baere T, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial-interim results. ASCO Meeting Abstracts 2013; 31 (15suppl):2512.
22. Johnson BE, Kris MG, Berry LD, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the Lung Cancer Mutation Consortium (LCMC). ASCO Meeting Abstracts 2013; 31 (15suppl):8019.
23. Le Tourneau C, Mitry E, Goncalves A, et al. Randomised phase II trial comparing therapy based on tumour molecular profiling versus conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Eur J Cancer 2013; 49:S194-S1194.
24. Carton E, Hollebecque A, Roquet F et al. Clinical outcomes according to molecular-guided therapy strategies in phase I for breast cancer patients. 49: Abs S418-S418.
25. Walker I, MacDonald F, Stuart H, et al. Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's Stratified Medicine Programme. ASCO Meeting Abstracts 2013; 31 (15suppl):11094.
26. Rollins BJ, MacConaill LE, Wagle N, et al. PROFILE: broadly based genomic testing for all patients at a major cancer center. ASCO Meeting Abstracts 2013; 31 (15suppl):1531.
27. Nowak F, Calvo F, Soria JC. Europe does it better: molecular testing across a National Healthcare System-The French Example. Am Soc Clin Oncol Educ Book 2013; 33.
28. Planchard D, Lacroix L, Le Chevalier T, et al. Abstract B45: upfront genomic testing in nonsmall cell lung cancer (NSCLC) patients: preliminary result of the MSN study. Clin Cancer Res 2012; 18 (3 Suppl):B45-B145.
29. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013; 31:1904-1911.
30. Tran B, Brown AM, Bedard PL, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 2013; 132:1547-1555.
31. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352:895-904.
32. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection J Clin Oncol 2011; 29:1236-1238.
33. Andre F, Nowak F, Arnedos M, et al. Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res 2012; 18:1555-1560.
34. Arnedos M, Andre F, Farace F, et al. The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. Mol Oncol 2012; 6:204-210.
35. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-472.
36. Pickrell WO, Rees MI, Chung SK. Next generation sequencing methodologies: an overview. Adv Protein Chem Struct Biol 2012; 89.
37. Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL, et al. Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol 2013; 31:1842-1848.
38. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11:685-696.
39. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458:97-101.
40. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009; 6:259-265.
41. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464:999-1005.
42. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-196.
43. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
44. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
45. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456:66-72.
46. Boca SM, Kinzler KW, Velculescu VE, et al. Patient-oriented gene set analysis for cancer mutation data. Genome Biol 2010; 11:R112.
47. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29:2972-2977.
48. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30:2956-2962.
49. Jacobsen A, Silber J, Harinath G, et al. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol 2013; 20:1325-1332.
50. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274.
51. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-158.
52. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-218.
53. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-892.
54. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
55. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-972.
56. Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-726.
57. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734-1739.
58. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209.
59. Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012; 18:3462-3469.
60. Murtaza M, Dawson SJ, Tsui DW, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112.
61. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359:366-377.
62. McMillinDW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013; 12:217-228.
63. Haibe-Kains B, El-Hachem N, Birkbak NJ, et al. Inconsistency in large pharmacogenomic studies. Nature 2013; 504:389-393.
64. Weinstein JN, Lorenzi PL. Cancer: discrepancies in drug sensitivity. Nature 2013; 504:381-383.
65. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-575.
66. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45:1113-1120.